Transition Bio operates an end‑to‑end condensate drug discovery platform that integrates droplet microfluidics with advanced cellular imaging. The platform generates molecular‑level data on how chemical compounds affect condensate systems, enabling precise assessment of drug candidates. Machine learning and AI are applied to optimize chemical matter and accelerate novel therapeutic development.
Funding
$76.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are considered "intractable" due to the lack of well-defined drug targets and binding mechanisms, hindering the development of effective therapeutics. Traditional drug discovery methods often fail to address the complexities of biomolecular condensates, which play a crucial role in disease pathways.
Solution
Transition Bio offers a proprietary drug discovery platform, Condensomics, that leverages droplet microfluidics and machine learning to analyze biomolecular condensates at the molecular level. The platform enables the identification of novel binding mechanisms and therapeutic hypotheses related to condensate biology, facilitating the development of therapeutics for previously intractable targets. By mapping condensates and their modulation in molecular detail, Transition Bio's platform generates proprietary datasets that are used to train algorithms for target discovery, validation, and drug design. This approach allows for the pursuit of intractable targets through well-defined condensates with specific therapeutic hypotheses, such as dissolving RNA foci to release sequestered RNA splicing factors or identifying structured binding pockets on proteins that regulate MYC.
Target Audience
Transition Bio's primary customers are pharmaceutical companies and research institutions seeking to develop novel therapeutics for intractable diseases by targeting biomolecular condensates.
Features
- Droplet microfluidics platform for high-throughput characterization of biomolecular condensates
- Machine learning algorithms for target discovery, target validation, and drug design
- Molecular-level analysis of condensates and their modulation
- Proprietary datasets for training AI models
- Identification of novel binding mechanisms and therapeutic hypotheses
- Capability to pursue intractable targets via well-defined condensates
- Focus on specific therapeutic hypotheses, such as dissolving RNA foci or targeting MYC regulation